Contributions
Abstract: P395
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: Cognitive impairment is common in people with multiple sclerosis (PwMS). The Neurotrax computerized multi-domain cognitive assessment battery (CAB-NT) motor domain includes both time to plan and carry out movement as well as motor dexterity, inter tap interval/variance. EDSS is traditionally utilized as a measure of disease impact but relies on visible aspects of hand function and does not include cognitive impact as it relates to dexterity. Due lesion load/location variability, visible disability of hand function might be independent of cognitive impairment. Improved analysis of disease impact in PwMS can provide better understanding of perceived/reported. Better measurements that define the role of each aspect of disease impact separately are needed to objectify the trajectory of disability and treatment efficacy in PwMS.
Objectives: Explore the relationship of 9-hole Peg Testing (9hPT) as a measure of manual dexterity to the information obtained by a standardized CAB-NT in PwMS.
Methods: PwMS prospectively underwent standardized CAB-NT, MACFIMS and 9hPT. Correlations between CAB-NT motor scores of a Global Cognitive Summary (GCS) without the motor score (e.g. average of the other 6 domains) and the 9HPT of the dominant hand (DH) as well as individual cognitive domain scores were explored.
Results: 63 PwMS, average age 45+/8.1, 71% female. The NT motor domain significantly predicted cognitive impairment as determined by MACFIMS [using oral SDMT] with Area Under Curve AUC of 0.76 and P< 0.0001. Scores of 9hPT DH tracked with CABNT individual domains: GCS p=00096, executive function p=.00065, attention p=.00034, information processing speed p=.0046, motor p=.00071, GoNoGo response time normal p=.00012, Catch Game Time to make 1st move p=.0467.
Conclusions: Global cognitive summary score (excluding motor score) and 9hPT are significantly correlated with CAB-NT motor score. Even after controlling for 9HPT, GCS without motor is still associated with CAB-NT motor score implying that this score is associated with cognition as measured by other domains. For PwMS CAB-NT motor domain is not completely explained by primary motor modalities. Manual dexterity measurements must include understanding of cognitive impact on dexterity as well as non-cognitive aspects to better understand PwMS disability perceptions and impact on ability. Improved analysis of disease impact/progression can provide a path to more informed treatment decisions/timing of change.
Disclosure: This study was not supported by outside funds
NJ: Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
JS- Nothing to disclose
AG- Nothing to disclose
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
LF- Nothing to disclose
DG- Nothing to disclose
CS- Nothing to disclose
JW- Nothing to disclose
Ilir Topalli- Nothing to disclose
Abstract: P395
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: Cognitive impairment is common in people with multiple sclerosis (PwMS). The Neurotrax computerized multi-domain cognitive assessment battery (CAB-NT) motor domain includes both time to plan and carry out movement as well as motor dexterity, inter tap interval/variance. EDSS is traditionally utilized as a measure of disease impact but relies on visible aspects of hand function and does not include cognitive impact as it relates to dexterity. Due lesion load/location variability, visible disability of hand function might be independent of cognitive impairment. Improved analysis of disease impact in PwMS can provide better understanding of perceived/reported. Better measurements that define the role of each aspect of disease impact separately are needed to objectify the trajectory of disability and treatment efficacy in PwMS.
Objectives: Explore the relationship of 9-hole Peg Testing (9hPT) as a measure of manual dexterity to the information obtained by a standardized CAB-NT in PwMS.
Methods: PwMS prospectively underwent standardized CAB-NT, MACFIMS and 9hPT. Correlations between CAB-NT motor scores of a Global Cognitive Summary (GCS) without the motor score (e.g. average of the other 6 domains) and the 9HPT of the dominant hand (DH) as well as individual cognitive domain scores were explored.
Results: 63 PwMS, average age 45+/8.1, 71% female. The NT motor domain significantly predicted cognitive impairment as determined by MACFIMS [using oral SDMT] with Area Under Curve AUC of 0.76 and P< 0.0001. Scores of 9hPT DH tracked with CABNT individual domains: GCS p=00096, executive function p=.00065, attention p=.00034, information processing speed p=.0046, motor p=.00071, GoNoGo response time normal p=.00012, Catch Game Time to make 1st move p=.0467.
Conclusions: Global cognitive summary score (excluding motor score) and 9hPT are significantly correlated with CAB-NT motor score. Even after controlling for 9HPT, GCS without motor is still associated with CAB-NT motor score implying that this score is associated with cognition as measured by other domains. For PwMS CAB-NT motor domain is not completely explained by primary motor modalities. Manual dexterity measurements must include understanding of cognitive impact on dexterity as well as non-cognitive aspects to better understand PwMS disability perceptions and impact on ability. Improved analysis of disease impact/progression can provide a path to more informed treatment decisions/timing of change.
Disclosure: This study was not supported by outside funds
NJ: Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
JS- Nothing to disclose
AG- Nothing to disclose
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
LF- Nothing to disclose
DG- Nothing to disclose
CS- Nothing to disclose
JW- Nothing to disclose
Ilir Topalli- Nothing to disclose